- Record: found
- Abstract: not found
- Article: not found
735MO Updated safety and efficacy from SURPASS, the phase I trial of ADP-A2M4CD8, a next-generation autologous T-cell receptor T-cell therapy, in previously treated patients with unresectable or metastatic tumors
D.S. Hong ,
A. Asch ,
E. Calvo ,
J. Zugazagoitia ,
J. Charlson ,
M.O. Butler ,
V. Moreno Garcia ,
A. Cervantes ,
B.A. Van Tine ,
D.P. Lawrence ,
M.L. Johnson ,
Q. Lin ,
T. Annareddy ,
F. Brophy ,
R. Broad ,
A. Derrac Soria ,
J-M. Navenot ,
J. Saro ,
E. Norry ,
J.M. Clarke
September 2022
September 2022
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.